COSYNTROPIN
LOE ApproachingNDAINTRAVENOUSSOLUTION
Approved
Feb 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
COSYNTROPIN by Novartis is clinical pharmacology cosyntropin, like acth, binds specific receptors in the plasma membrane of adrenal cortical cells in the zona fasciculata. First approved in 2008.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Cosyntropin is a synthetic analog of adrenocorticotropic hormone (ACTH) administered intravenously as a solution. It binds to adrenal cortical cell receptors, activating adenylate cyclase to stimulate glucocorticoid production via cholesterol conversion. Used diagnostically to assess adrenal function and therapeutically in adrenal insufficiency.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure; team focus likely shifting to lifecycle management and cost optimization rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Cosyntropin, like ACTH, binds specific receptors in the plasma membrane of adrenal cortical cells in the zona fasciculata. The hormone-receptor complex activates adenylate cyclase, which stimulates the production of cyclic AMP. This leads to the conversion of cholesterol to…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Cosyntropin Versus Epidural Blood Patch (EBP) for Treatment of Treatment of Post Dural Puncture Headache
Started Aug 2010
29 enrolled
Postdural Puncture Headache
Career Relevance
Cosyntropin offers limited career growth opportunity given its niche indication, approaching LOE status, and minimal linked job openings. Roles focus on cost management, market access negotiations, and defensive commercial strategy rather than expansion.
Brand Manager
Worked on COSYNTROPIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.